annb0t
Top 20
Mesoblast Limited
If Approved, Remestemcel-L will be the First Allogeneic âOff-the-Shelfâ Cellular Medicine in the US, and the First Therapy for Children Under 12 Years Old with SR-aGVHD.
NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administrationâs (FDA) Office of Therapeutic Products (OTP) has accepted the Comp...
>>> Read more: FDA Accepts Mesoblastâs Resubmission of the Biologic License Application for Remestemcel-L In Children with Steroid-Refractory Acute Graft Versus Host Disease as a Complete Response and Sets Goal Date of August 2, 2023
If Approved, Remestemcel-L will be the First Allogeneic âOff-the-Shelfâ Cellular Medicine in the US, and the First Therapy for Children Under 12 Years Old with SR-aGVHD.
NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administrationâs (FDA) Office of Therapeutic Products (OTP) has accepted the Comp...
>>> Read more: FDA Accepts Mesoblastâs Resubmission of the Biologic License Application for Remestemcel-L In Children with Steroid-Refractory Acute Graft Versus Host Disease as a Complete Response and Sets Goal Date of August 2, 2023
